Novonesis (Novozymes) A/S (NSIS-B) - Total Liabilities

Latest as of March 2026: Dkr5.60 Billion DKK ≈ $876.71 Million USD

Based on the latest financial reports, Novonesis (Novozymes) A/S (NSIS-B) has total liabilities worth Dkr5.60 Billion DKK (≈ $876.71 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore NSIS-B long-term asset investment ratio to see how much of total assets are deployed in long-term investments.

Novonesis (Novozymes) A/S - Total Liabilities Trend (2002–2025)

This chart illustrates how Novonesis (Novozymes) A/S's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see Novonesis (Novozymes) A/S asset portfolio.

Novonesis (Novozymes) A/S Competitors by Total Liabilities

The table below lists competitors of Novonesis (Novozymes) A/S ranked by their total liabilities.

Company	Country	Total Liabilities
China Hongqiao Group Ltd F:H0Q	Germany	€103.67 Billion
China Life Insurance Company Limited F:CHL	Germany	€7.10 Trillion
Pembina Pipeline Corp TO:PPL	Canada	CA$19.27 Billion
Arch Capital Group Ltd F:RSK	Germany	€57.26 Billion
ON Semiconductor Corporation NASDAQ:ON	USA	$6.25 Billion
PetroChina Company Limited F:PC6	Germany	€1.20 Trillion
Capitec Bank Holdings Ltd JSE:CPI	South Africa	ZAC196.76 Billion
Celltrion Inc KO:068270	Korea	₩5.34 Trillion

Liability Composition Analysis (2002–2025)

This chart breaks down Novonesis (Novozymes) A/S's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See Novonesis (Novozymes) A/S balance sheet independence to measure how much of total assets are equity-financed.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	1.67	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	0.51	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.34	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Novonesis (Novozymes) A/S's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Novonesis (Novozymes) A/S (2002–2025)

The table below shows the annual total liabilities of Novonesis (Novozymes) A/S from 2002 to 2025.

Year	Total Liabilities	Change
2025-12-31	Dkr5.49 Billion ≈ $859.56 Million	+36.68%
2024-12-31	Dkr4.02 Billion ≈ $628.90 Million	-71.37%
2023-12-31	Dkr14.04 Billion ≈ $2.20 Billion	+2.07%
2022-12-31	Dkr13.76 Billion ≈ $2.15 Billion	+9.51%
2021-12-31	Dkr12.56 Billion ≈ $1.97 Billion	+35.56%
2020-12-31	Dkr9.27 Billion ≈ $1.45 Billion	+3.45%
2019-12-31	Dkr8.96 Billion ≈ $1.40 Billion	+8.45%
2018-12-31	Dkr8.26 Billion ≈ $1.29 Billion	+16.23%
2017-12-31	Dkr7.11 Billion ≈ $1.11 Billion	+2.78%
2016-12-31	Dkr6.91 Billion ≈ $1.08 Billion	+11.55%
2015-12-31	Dkr6.20 Billion ≈ $969.72 Million	-13.27%
2014-12-31	Dkr7.15 Billion ≈ $1.12 Billion	+31.36%
2013-12-31	Dkr5.44 Billion ≈ $851.13 Million	-1.89%
2012-12-31	Dkr5.54 Billion ≈ $867.56 Million	+10.50%
2011-12-31	Dkr5.02 Billion ≈ $785.10 Million	+5.49%
2010-12-31	Dkr4.76 Billion ≈ $744.27 Million	-5.60%
2009-12-31	Dkr5.04 Billion ≈ $788.39 Million	-7.52%
2008-12-31	Dkr5.45 Billion ≈ $852.54 Million	+4.71%
2007-12-31	Dkr5.20 Billion ≈ $814.20 Million	+13.82%
2006-12-31	Dkr4.57 Billion ≈ $715.32 Million	+30.07%
2005-12-31	Dkr3.52 Billion ≈ $549.95 Million	+8.42%
2004-12-31	Dkr3.24 Billion ≈ $507.23 Million	-6.25%
2003-12-31	Dkr3.46 Billion ≈ $541.03 Million	-15.70%
2002-12-31	Dkr4.10 Billion ≈ $641.79 Million	--

About Novonesis (Novozymes) A/S

CO:NSIS-B Denmark Specialty Chemicals

Market Cap

$27.65 Billion

Dkr176.71 Billion DKK

Market Cap Rank

#969 Global

#6 in Denmark

Share Price

Dkr428.40

Change (1 day)

-0.23%

52-Week Range

Dkr342.00 - Dkr463.00

All Time High

Dkr508.57